MXPA05013827A - Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. - Google Patents
Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.Info
- Publication number
- MXPA05013827A MXPA05013827A MXPA05013827A MXPA05013827A MXPA05013827A MX PA05013827 A MXPA05013827 A MX PA05013827A MX PA05013827 A MXPA05013827 A MX PA05013827A MX PA05013827 A MXPA05013827 A MX PA05013827A MX PA05013827 A MXPA05013827 A MX PA05013827A
- Authority
- MX
- Mexico
- Prior art keywords
- cpt
- vascular damaging
- colorectal cancer
- compositions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un metodo para la produccion de un efecto de dano vascular en un animal de sangre caliente, tal como un humano, que esta siendo tratado opcionalmente con radiacion ionizante; particularmente un metodo para el tratamiento de un cancer que involucra un tumor solido, tal como cancer colorrectal, que comprende uno de los siguientes: la administracion de ZD6126 en combinacion con 5-FU; la administracion de ZD6126 en combinacion con CPT-11, y la administracion de ZD6126 en combinacion con 5-FU y CPT-11. Tambien se reivindican composiciones farmaceuticas y estuches que comprenden uno de: ZD6126 y CPT-11, y ZD6126 y 5-FU y CPT-11. Se reivindica adicionalmente el uso de uno de los siguientes: ZD6126 y 5-FU; ZD6126 y CPT-11, y ZD6126 y 5-FU y CPT-11, en la fabricacion de un medicamento para uso en la produccion de un efecto de dano vascular en un animal de sangre caliente, que esta siendo tratado opcionalmente con radiacion ionizante.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314097A GB0314097D0 (en) | 2003-06-18 | 2003-06-18 | Combination therapy |
| GB0316181A GB0316181D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
| PCT/GB2004/002624 WO2004112801A2 (en) | 2003-06-18 | 2004-06-18 | Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05013827A true MXPA05013827A (es) | 2006-03-13 |
Family
ID=33542667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05013827A MXPA05013827A (es) | 2003-06-18 | 2004-06-18 | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060142239A1 (es) |
| EP (1) | EP1658084A2 (es) |
| JP (1) | JP2006527753A (es) |
| KR (1) | KR20060036058A (es) |
| AU (1) | AU2004248968A1 (es) |
| BR (1) | BRPI0411567A (es) |
| CA (1) | CA2529409A1 (es) |
| IL (1) | IL172560A0 (es) |
| MX (1) | MXPA05013827A (es) |
| NO (1) | NO20055888L (es) |
| WO (1) | WO2004112801A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2569277A1 (en) * | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| US20090118340A1 (en) * | 2007-10-12 | 2009-05-07 | Jerzy Gebicki | Method for inhibiting and/or preventing formation of cancer metastases and seconddary malignant cancers |
| WO2024063569A1 (ko) * | 2022-09-22 | 2024-03-28 | (의) 삼성의료재단 | 종양 혈관 파괴용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4864021A (en) * | 1984-10-30 | 1989-09-05 | Otsuka Pharmaceutical Co., Ltd. | 5-fluorouracil derivatives |
| GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CZ20023231A3 (cs) * | 2000-03-31 | 2003-01-15 | Angiogene Pharmaceuticals Ltd. | Farmaceutické prostředky obsahující činidla poąkozující cévy |
| EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US20050277627A1 (en) * | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
| US6720323B2 (en) * | 2000-07-07 | 2004-04-13 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| DE60311788T2 (de) * | 2002-04-16 | 2007-11-22 | Astrazeneca Ab | Kombinationstherapie zur behandlung von krebs |
-
2004
- 2004-06-18 EP EP04742979A patent/EP1658084A2/en not_active Withdrawn
- 2004-06-18 AU AU2004248968A patent/AU2004248968A1/en not_active Abandoned
- 2004-06-18 JP JP2006516444A patent/JP2006527753A/ja active Pending
- 2004-06-18 MX MXPA05013827A patent/MXPA05013827A/es not_active Application Discontinuation
- 2004-06-18 KR KR1020057024244A patent/KR20060036058A/ko not_active Application Discontinuation
- 2004-06-18 CA CA002529409A patent/CA2529409A1/en not_active Abandoned
- 2004-06-18 WO PCT/GB2004/002624 patent/WO2004112801A2/en not_active Application Discontinuation
- 2004-06-18 BR BRPI0411567-8A patent/BRPI0411567A/pt not_active Application Discontinuation
- 2004-06-18 US US10/561,183 patent/US20060142239A1/en not_active Abandoned
-
2005
- 2005-12-12 NO NO20055888A patent/NO20055888L/no not_active Application Discontinuation
- 2005-12-13 IL IL172560A patent/IL172560A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004112801A2 (en) | 2004-12-29 |
| BRPI0411567A (pt) | 2006-08-01 |
| WO2004112801A3 (en) | 2005-03-24 |
| KR20060036058A (ko) | 2006-04-27 |
| AU2004248968A1 (en) | 2004-12-29 |
| NO20055888L (no) | 2006-03-16 |
| JP2006527753A (ja) | 2006-12-07 |
| US20060142239A1 (en) | 2006-06-29 |
| EP1658084A2 (en) | 2006-05-24 |
| CA2529409A1 (en) | 2004-12-29 |
| IL172560A0 (en) | 2006-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| NO20053649L (no) | Kombinasjonsterapi | |
| EP1971338B8 (en) | Combination of zd6474 and pemetrexed | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
| MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. | |
| GB0406445D0 (en) | Combination therapy | |
| GB0223379D0 (en) | Combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |